Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population

Go back to Moderna Announces First Participants Dosed in Phase 2/3 Study of COVID-19 Vaccine Candidate in Pediatric Population
Marina Biotech, Inc. (NASDAQ: MRNA) Delayed: 163.15 +2.65 (1.65%)
Previous Close $160.50    52 Week High $0.52 
Open $165.78    52 Week Low $0.08 
Day High $169.02    P/E N/A 
Day Low $160.82    EPS $-3.80 
Volume 11,949,564